Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small-Cell Lung Carcinoma NSCLC: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Non-Small-Cell Lung Carcinoma NSCLC: 3 US clinical trials tracked, none currently recruiting.
Non-Small-Cell Lung Carcinoma NSCLC is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 3 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-carcinoma-nsclc
OPEN 0 | RECR 0% | LATE 3 | EARLY 0 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Non-Small-Cell Lung Carcinoma NSCLC has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small-Cell Lung Carcinoma NSCLC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small-Cell Lung Carcinoma NSCLC is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
AstraZeneca
NCT02453282
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
AstraZeneca
NCT02542293
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
NCT03003962
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small-Cell Lung Carcinoma NSCLC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small-Cell Lung Carcinoma NSCLC trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small-Cell Lung Carcinoma NSCLC page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Non-Small-Cell Lung Carcinoma NSCLC trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- AstraZeneca sponsors the most Non-Small-Cell Lung Carcinoma NSCLC trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small-Cell Lung Carcinoma NSCLC condition card totals 3 registered trials; most-linked intervention Pemetrexed + cisplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.